-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Clinical Discussant for Lymphoid Malignancies

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium II: Striking a Balance - Benefit-Risk in Drug Approvals
Monday, December 11, 2023, 2:45 PM-4:15 PM

Jeff P. Sharman, MD

Willamette Valley Cancer Institute and Research Center, Eugene, OR

Disclosures: Sharman: Genentech: Consultancy; Beigene: Consultancy; BMS: Consultancy; AbbVie: Consultancy; Astra Zeneca: Consultancy; Genmab: Consultancy; Lilly: Consultancy; Merck: Consultancy; Novartis: Consultancy.

See more of: ASH-FDA Joint Symposium II: Striking a Balance - Benefit-Risk in Drug Approvals
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>